Alere

/Alere
­
12 02, 2016

Abbott Acquires Alere to Gain Leadership in Point-of-care Segment

By |February 12th, 2016|Abbott Laboratories, Alere|Comments Off on Abbott Acquires Alere to Gain Leadership in Point-of-care Segment

Abbott Laboratories has reached an agreement to acquire Alere Inc for $5.8 billion. In a press release, Abbott said that once the transaction is completed, it will become the leading diagnostics provider of point of care testing. Alere's complementary technologies will help Abbott provide better care for patients by meeting the growing demand for fast, [...]

9 10, 2015

Alere Expands Support to OAFLA in the Fight against HIV

By |October 9th, 2015|Alere, HIV|Comments Off on Alere Expands Support to OAFLA in the Fight against HIV

Global diagnostic device and service provider Alere recently reiterated its commitment to support the Organization of African First Ladies against HIV/AIDS (OAFLA) in the fight against HIV. OAFLA is an alliance of African First Ladies that was established to check HIV transmission. It is a collective voice for Africa’s most vulnerable people, women and children [...]

10 04, 2015

Alere Inc. Gets FDA Approval for i Strep A Test

By |April 10th, 2015|Alere, Triage BNP Test|Comments Off on Alere Inc. Gets FDA Approval for i Strep A Test

Alere Inc., a leader in rapid point of care diagnostics market recently announced that its i Strep A test has won FDA (Food and Drug Administration) 510(K) clearance. Alere’s i Strep A test is the first molecular test that detects group A streptococcus (GAS) bacteria in throat swab specimens in 8 minutes or less. This [...]

10 03, 2015

March 10 is National Women and Girls HIV/AIDS Awareness Day

By |March 10th, 2015|Alere, HIV Testing|Comments Off on March 10 is National Women and Girls HIV/AIDS Awareness Day

According to the Office on Women's Health of the U.S. Department of Health and Human Services (HSS), about one in four people living with HIV are women, and about 217,000 women - 80% of whom are of childbearing age (15 to 44) - are HIV-positive. Every year starting 2006, March 10 has been observed as [...]

9 01, 2015

FDA Grants CLIA Waiver for HIV Combo Test

By |January 9th, 2015|Alere, HIV Combo Test|Comments Off on FDA Grants CLIA Waiver for HIV Combo Test

According to the Centers for Disease Control and Prevention (CDC), there are approximately 1.1 million Americans living with HIV. The U.S. Food and Drug Administration (FDA) has recently granted a Clinical Laboratory Improvement Amendments (CLIA) Waiver for the Alere Determine HIV-1/2 Ag/Ab Combo test. The Centers for Medicare & Medicaid Services (CMS) regulates all laboratory [...]

31 10, 2014

Optum Buying Alere Health for $600 Million

By |October 31st, 2014|Alere, Infectious Diseases|Comments Off on Optum Buying Alere Health for $600 Million

With dynamic shifts in the market, there has been a surge in integrated healthcare models. Optum, a unit of Minnesota-based UnitedHealth Group Inc., has made headlines with its decision to buy Alera Health in a $600 million all-cash transaction. Alere Health is a division of Alere Inc., a provider of rapid diagnostics for infectious disease, [...]

9 09, 2014

National Cholesterol Education Month – Focus on Screening

By |September 9th, 2014|Alere, Blood Testing|Comments Off on National Cholesterol Education Month – Focus on Screening

In addition to smoking and blood pressure, cholesterol is a major controllable risk factor for coronary heart disease and stroke. Heart disease is the number one cause of death in the United States. More than seventy-one million American adults have high cholesterol. September is observed every year as the National Month of Cholesterol Education. The [...]

22 08, 2014

Need for New Infant HIV-1 Prevention Methods Stressed

By |August 22nd, 2014|Abbott Laboratories, Alere|Comments Off on Need for New Infant HIV-1 Prevention Methods Stressed

The number of children infected with HIV has risen dramatically in developing countries. Symptoms of the infection in children include recurrent fungal infections, growth failure and behavioral abnormalities. Antibody testing is the most commonly used method to diagnose HIV infection. According to the Joint United Nations Program on HIV/AIDS (UNAIDS), an estimated 1,000 babies are [...]

8 07, 2014

Alere’s Rapid Influenza Diagnostic Test Gets FDA Approval

By |July 8th, 2014|Alere, Laboratory Equipment|Comments Off on Alere’s Rapid Influenza Diagnostic Test Gets FDA Approval

Alere Inc., a global leader in point-of-care rapid diagnostics and other health information solutions, has received FDA clearance for the Alere™ i Influenza A and B Test. This is the first and only molecular test to identify and differentiate influenza A and B virus in less than 15 minutes. This in-vitro immunochromatographic assay is designed [...]